|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||156.36 - 159.70|
|52-week range||134.09 - 175.91|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||23.83|
|Earnings date||27 Apr 2023 - 01 May 2023|
|Forward dividend & yield||5.92 (3.74%)|
|Ex-dividend date||13 Apr 2023|
|1y target est||163.87|
Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. Vertex has a new potential blockbuster drug on the horizon.
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world. Events include two Allergan Medical Institute (AMI) symposia, Meet the Expert sessions and an interactive exhibition booth that practitioners can explore. Throug
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.